Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms22115457 http://scihub22266oqcxt.onion/10.3390/ijms22115457 34064287!8196831!34064287     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Mol+Sci 2021 ; 22 (11): ä Nephropedia Template TP {{tp|p=34064287|t=2021. Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?|pdf=|usr=}}{{34064287}} gab.com Text Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=34064287 #FOAvip Therapeutics and vaccines against the COVID-19 pandemic need to be developed rapidly and efficiently, given its severity. To maximize the efficiency and productivity of drug development, the world has adopted disruptive technologies and approaches in various drug development areas. Telehealth, characterized by the heavy use of digital technologies; drug repositioning strategies, aided by computational breakthroughs; and data tracking tool hubs, enabling real-time information sharing, have received much attention. Moreover, drug developers have engaged in open innovation by establishing various types of collaborations, many of which have been carried out across nations and enterprises. Finally, regulatory agencies have attempted to operate on a more flexible review basis than before. Although such disruptive approaches have partly reshaped drug development practices, issues and challenges remain before the completion of this paradigm shift in conventional drug development practices for the post-pandemic era. In this review, we have highlighted the role of a collaborative community of experts in order to figure out how disruptive technologies can be fully integrated into the current drug development practices and improve drug development efficiency for the post-pandemic era. Twit Text FOAVip Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=34064287 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34064287 #FOAvip English Wikipedia <ref>{{Cite pmid|34064287}}</ref> Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices? #MMPMID34064287 Won JH; Lee H Int J Mol Sci 2021[May]; 22 (11): ä PMID34064287show ga Therapeutics and vaccines against the COVID-19 pandemic need to be developed rapidly and efficiently, given its severity. To maximize the efficiency and productivity of drug development, the world has adopted disruptive technologies and approaches in various drug development areas. Telehealth, characterized by the heavy use of digital technologies; drug repositioning strategies, aided by computational breakthroughs; and data tracking tool hubs, enabling real-time information sharing, have received much attention. Moreover, drug developers have engaged in open innovation by establishing various types of collaborations, many of which have been carried out across nations and enterprises. Finally, regulatory agencies have attempted to operate on a more flexible review basis than before. Although such disruptive approaches have partly reshaped drug development practices, issues and challenges remain before the completion of this paradigm shift in conventional drug development practices for the post-pandemic era. In this review, we have highlighted the role of a collaborative community of experts in order to figure out how disruptive technologies can be fully integrated into the current drug development practices and improve drug development efficiency for the post-pandemic era. |*COVID-19 Drug Treatment[MESH] |Drug Development/*methods[MESH] |Drug Repositioning/*methods[MESH] |Humans[MESH] |Medical Informatics/*methods[MESH] |Pandemics[MESH] |SARS-CoV-2[MESH]Can the COVID-19 Pandemic Disrupt the Current Drug Development Practic(epmc).pdf DeepDyve Pubget Overpricing